Ultrasound Obstet Gynecol. 2020 Aug;56(2):206-214. doi: 10.1002/uog.21905. Epub 2020 Jul 10.

First-trimester pre-eclampsia biomarker profiles in Asian population: multicenter cohort study.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology

P Chaemsaithong, D Sahota, R K Pooh, M Zheng, R Ma, N Chaiyasit, K Koide, S W Shaw, S Seshadri, M Choolani, T Panchalee, P Yapan, W S Sim, A Sekizawa, Y Hu, A Shiozaki, S Saito, T Y Leung, L C Poon

PMID: 31671479 DOI: 10.1002/uog.21905

Abstract

OBJECTIVES: To (i) evaluate the applicability of the European-derived biomarker multiples of the median (MoM) formulae for risk assessment of preterm pre-eclampsia (PE) in seven Asian populations, spanning the east, southeast and south regions of the continent, (ii) perform quality-assurance (QA) assessment of the biomarker measurements and (iii) establish criteria for prospective ongoing QA assessment of biomarker measurements.

METHODS: This was a prospective, non-intervention, multicenter study in 4023 singleton pregnancies, at 11 to 13 + 6 weeks' gestation, in 11 recruiting centers in China, Hong Kong, India, Japan, Singapore, Taiwan and Thailand. Women were screened for preterm PE between December 2016 and June 2018 and gave written informed consent to participate in the study. Maternal and pregnancy characteristics were recorded and mean arterial pressure (MAP), mean uterine artery pulsatility index (UtA-PI) and maternal serum placental growth factor (PlGF) were measured in accordance with The Fetal Medicine Foundation (FMF) standardized measurement protocols. MAP, UtA-PI and PlGF were transformed into MoMs using the published FMF formulae, derived from a largely Caucasian population in Europe, which adjust for gestational age and covariates that affect directly the biomarker levels. Variations in biomarker MoM values and their dispersion (SD) and cumulative sum tests over time were evaluated in order to identify systematic deviations in biomarker measurements from the expected distributions.

RESULTS: In the total screened population, the median (95% CI) MoM values of MAP, UtA-PI and PlGF were 0.961 (0.956-0.965), 1.018 (0.996-1.030) and 0.891 (0.861-0.909), respectively. Women in this largely Asian cohort had approximately 4% and 11% lower MAP and PlGF MoM levels, respectively, compared with those expected from normal median formulae, based on a largely Caucasian population, whilst UtA-PI MoM values were similar. UtA-PI and PlGF MoMs were beyond the 0.4 to 2.5 MoM range (truncation limits) in 16 (0.4%) and 256 (6.4%) pregnancies, respectively. QA assessment tools indicated that women in all centers had consistently lower MAP MoM values than expected, but were within 10% of the expected value. UtA-PI MoM values were within 10% of the expected value at all sites except one. Most PlGF MoM values were systematically 10% lower than the expected value, except for those derived from a South Asian population, which were 37% higher.

CONCLUSIONS: Owing to the anthropometric differences in Asian compared with Caucasian women, significant differences in biomarker MoM values for PE screening, particularly MAP and PlGF MoMs, were noted in Asian populations compared with the expected values based on European-derived formulae. If reliable and consistent patient-specific risks for preterm PE are to be reported, adjustment for additional factors or development of Asian-specific formulae for the calculation of biomarker MoMs is required. We have also demonstrated the importance and need for regular quality assessment of biomarker values. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

Keywords: Asian population; CUSUM; European population; PlGF; biomarker; blood pressure; mean arterial pressure; placental growth factor; pre-eclampsia; prediction; pulsatility index; quality assurance; uterine artery

References

1. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Pre-eclampsia. N Engl J Med 2017; 377: 613-622. - PubMed
2. Wright D, Rolnik DL, Syngelaki A, de Paco Matallana C, Machuca M, de Alvarado M, Mastrodima S, Tan MY, Shearing S, Persico N, Jani JC, Plasencia W, Papaioannou G, Molina FS, Poon LC, Nicolaides KH. Aspirin for Evidence-Based Pre-eclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. Am J Obstet Gynecol 2018; 218: 612.e611-616. - PubMed
3. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335: 974. - PubMed
4. Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke 2009; 40: 1176-1180. - PubMed
5. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009; 53: 944-951. - PubMed
6. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Pre-eclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension 2010; 56: 166-171. - PubMed
7. van Wassenaer AG, Westera J, van Schie PE, Houtzager BA, Cranendonk A, de Groot L, Ganzevoort W, Wolf H, de Vries JI. Outcome at 4.5 years of children born after expectant management of early-onset hypertensive disorders of pregnancy. Am J Obstet Gynecol 2011; 204: 510.e511-519. - PubMed
8. Akhter T, Larsson M, Wikstrom AK, Naessen T. Thicknesses of individual layers of artery wall indicate increased cardiovascular risk in severe pre-eclampsia. Ultrasound Obstet Gynecol 2014; 43: 675-680. - PubMed
9. Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS. Maternal morbidity associated with early-onset and late-onset pre-eclampsia. Obstet Gynecol 2014; 124: 771-781. - PubMed
10. Heida KY, Franx A, van Rijn BB, Eijkemans MJ, Boer JM, Verschuren MW, Oudijk MA, Bots ML, van der Schouw YT. Earlier Age of Onset of Chronic Hypertension and Type 2 Diabetes Mellitus After a Hypertensive Disorder of Pregnancy or Gestational Diabetes Mellitus. Hypertension 2015; 66: 1116-1122. - PubMed
11. Veerbeek JH, Hermes W, Breimer AY, van Rijn BB, Koenen SV, Mol BW, Franx A, de Groot CJ, Koster MP. Cardiovascular disease risk factors after early-onset pre-eclampsia, late-onset pre-eclampsia, and pregnancy-induced hypertension. Hypertension 2015; 65: 600-606. - PubMed
12. Theilen LH, Meeks H, Fraser A, Esplin MS, Smith KR, Varner MW. Long-term mortality risk and life expectancy following recurrent hypertensive disease of pregnancy. Am J Obstet Gynecol 2018; 219: 107.e101-106. - PubMed
13. Hammad IA, Meeks H, Fraser A, Theilen LH, Esplin MS, Smith KR, Varner MW. Risks of Cause-specific Mortality in Offspring of Pregnancies Complicated by Hypertensive Disease of Pregnancy. Am J Obstet Gynecol 2019. DOI:10.1016/j.ajog.2019.07.024. - PubMed
14. Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH. A competing risks model in early screening for pre-eclampsia. Fetal Diagn Ther 2012; 32: 171-178. - PubMed
15. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for pre-eclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013; 33: 8-15. - PubMed
16. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for pre-eclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015; 213: 62.e61-10. - PubMed
17. O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol 2016; 214: 103.e101-112. - PubMed
18. O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, Akolekar R, Cicero S, Janga D, Jani J, Molina FS, de Paco Matallana C, Papantoniou N, Persico N, Plasencia W, Singh M, Nicolaides KH. Accuracy of competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol 2017; 49: 751-755. - PubMed
19. Wright D, Tan MY, O'Gorman N, Poon LC, Syngelaki A, Wright A, Nicolaides KH. Predictive performance of the competing risk model in screening for pre-eclampsia. Am J Obstet Gynecol 2019; 220: 199.e1-13. - PubMed
20. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 30: 742-749. - PubMed
21. Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation. Fetal Diagn Ther 2012; 31: 42-48. - PubMed
22. Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, McAuliffe F, da Silva Costa F, von Dadelszen P, McIntyre HD, Kihara AB, Di Renzo GC, Romero R, D'Alton M, Berghella V, Nicolaides KH, Hod M. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145 Suppl 1: 1-33. - PubMed
23. Tayyar A, Guerra L, Wright A, Wright D, Nicolaides KH. Uterine artery pulsatility index in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 689-697. - PubMed
24. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 591-598. - PubMed
25. Wright A, Wright D, Ispas CA, Poon LC, Nicolaides KH. Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 698-706. - PubMed
26. Ridding G, Hyett JA, Sahota D, McLennan AC. Assessing quality standards in measurement of uterine artery pulsatility index at 11 to 13 + 6 weeks' gestation. Ultrasound Obstet Gynecol 2015; 46: 299-305. - PubMed
27. Rolnik DL, da Silva Costa F, Sahota D, Hyett J, McLennan A. Quality assessment of uterine artery Doppler measurement in first trimester combined screening for pre-eclampsia. Ultrasound Obstet Gynecol 2019; 53: 245-250. - PubMed
28. Sahota DS, Leung TY, Leung TN, Chan OK, Lau TK. Fetal crown-rump length and estimation of gestational age in an ethnic Chinese population. Ultrasound Obstet Gynecol 2009; 33: 157-160. - PubMed
29. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves JW, Hill MN, Jones DH, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J Clin Hypertens (Greenwich) 2005; 7: 102-109. - PubMed
30. Roberts L, Chaemsaithong P, Sahota DS, Nicolaides KH, Poon LCY. Protocol for measurement of mean arterial pressure at 10-40weeks' gestation. Pregnancy Hypertens 2017; 10: 155-160. - PubMed
31. Rolnik DL, Wright D, Poon LCY, Syngelaki A, O'Gorman N, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Nicolaides KH. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 2017; 50: 492-495. - PubMed
32. Tan MY, Syngelaki A, Poon LC, Rolnik DL, O'Gorman N, Delgado JL, Akolekar R, Konstantinidou L, Tsavdaridou M, Galeva S, Ajdacka U, Molina FS, Persico N, Jani JC, Plasencia W, Greco E, Papaioannou G, Wright A, Wright D, Nicolaides KH. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol 2018; 52: 186-195. - PubMed
33. Sahota DS, Leung WC, To WK, Chan WP, Lau TK, Leung TY. Quality assurance of nuchal translucency for prenatal fetal Down syndrome screening. J Matern Fetal Neonatal Med 2012; 25: 1039-1043. - PubMed
34. Cheng Y, Leung TY, Law LW, Ting YH, Law KM, Sahota DS. First trimester screening for pre-eclampsia in Chinese pregnancies: case-control study. BJOG 2018; 125: 442-449. - PubMed
35. Hawkins DM, Olwell PH. Cumulative Sum Charts and Charting for Quality Improvement. Springer Verlag: New York, NY, 1998. - PubMed
36. Woley HP. The Normal Variation of the Systolic Blood Pressure. JAMA 1910; 55: 121-123. - PubMed
37. Cadbury WW. The Blood Pressure of Normal Cantonese Students. Arch Intern Med 1922; 30: 262-377. - PubMed
38. Kao CL. Blood Pressure of Hunan Students. Nat M J China 1922; 8: 10. - PubMed
39. Alvarez WC. Blood Pressures in Fifteen Thousand University Freshmen. Arch Intern Med 1923; 32: 17-30. - PubMed
40. Symonds S. The Blood Pressure of Healthy Men and Women. JAMA 1923; 80: 232-236. - PubMed
41. Kilborn LG. A Note on the Blood Pressure of Primitive Races With Special Reference to the Miao of Kweichow. Chinese J Physiol 1937; 21: 135. - PubMed
42. Morse WR, Beh YT. Blood Pressure Amongst Aboriginal Ethnic Groups Szechwan Provice, West China. Lancet 1937; 1: 966-967. - PubMed
43. Masuo K, Mikami H, Ogihara T, Tuck ML. Weight gain-induced blood pressure elevation. Hypertension 2000; 35: 1135-1140. - PubMed
44. Messerli FH, Sundgaard-Riise K, Reisin ED, Dreslinski GR, Ventura HO, Oigman W, Frohlich ED, Dunn FG. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med 1983; 99: 757-761. - PubMed
45. Collis T, Devereux RB, Roman MJ, de Simone G, Yeh J, Howard BV, Fabsitz RR, Welty TK. Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation 2001; 103: 820-825. - PubMed
46. Hall JE, Brands MW, Hildebrandt DA, Kuo J, Fitzgerald S. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz J Med Biol Res 2000; 33: 605-618. - PubMed
47. Misra VK, Hobel CJ, Sing CF. Ethnic heterogeneity in the longitudinal effects of placental vascular blood flow on birthweight. Am J Obstet Gynecol 2008; 198: 72.e71-78. - PubMed
48. Audette MC, Levytska K, Lye SJ, Melamed N, Kingdom JC. Parental ethnicity and placental maternal vascular malperfusion pathology in healthy nulliparous women. Placenta 2018; 66: 40-46. - PubMed
49. Han J, Liu H, Xu ZP, Cuckle H, Sahota D, Li DZ, Liao C. Maternal serum PlGF (placental growth factor) in Chinese women in the first trimester undergoing screening for Down syndrome. Eur J Obstet Gynecol Reprod Biol 2016; 201: 166-170. - PubMed
50. Perry IJ, Beevers DG, Whincup PH, Bareford D. Predictors of ratio of placental weight to fetal weight in multiethnic community. BMJ 1995; 310: 436-439. - PubMed
51. Sivarao S, Vidyadaran MK, Jammal AB, Zainab S, Goh YM, Ramesh KN. Weight, volume and surface area of placenta of normal pregnant women and their relation to maternal and neonatal parameters in Malay, Chinese and Indian ethnic groups. Placenta 2002; 23: 691-696. - PubMed
52. Salafia CM, Zhang J, Charles AK, Bresnahan M, Shrout P, Sun W, Maas EM. Placental characteristics and birthweight. Paediatr Perinat Epidemiol 2008; 22: 229-239. - PubMed
53. Chaemsaithong P, Ting YH, Cheng KYY, Poon CYL, Leung TY, Sahota DS. Uterine artery pulsatility index in the first trimester: assessment of intersonographer and intersampling site measurement differences. J Matern Fetal Neonatal Med 2018; 31: 2276-2283. - PubMed
54. Ridding G, Schluter PJ, Hyett JA, McLennan AC. Influence of sampling site on uterine artery Doppler indices at 11-13 + 6 weeks gestation. Fetal Diagn Ther 2015; 37: 310-315. - PubMed
55. Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH. Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol 2009; 33: 657-664. - PubMed

Publication Types

• Journal Article
• Research Support, Non-U.S. Gov't